- Home
- WFG vs ROIV Comparison
WFG vs ROIV Comparison
Compare WFG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- ROIV
- Stock Information
- Founded
- WFG 1955
- ROIV 2014
- Country
- WFG Canada
- ROIV United Kingdom
- Employees
- WFG N/A
- ROIV N/A
- Industry
- WFG
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- WFG
- ROIV Health Care
- Exchange
- WFG Nasdaq
- ROIV Nasdaq
- Market Cap
- WFG 7.5B
- ROIV 8.4B
- IPO Year
- WFG N/A
- ROIV N/A
- Fundamental
- Price
- WFG $75.10
- ROIV $10.79
- Analyst Decision
- WFG Buy
- ROIV Buy
- Analyst Count
- WFG 3
- ROIV 4
- Target Price
- WFG $105.00
- ROIV $17.50
- AVG Volume (30 Days)
- WFG 166.7K
- ROIV 5.9M
- Earning Date
- WFG 04-22-2025
- ROIV 05-29-2025
- Dividend Yield
- WFG 1.70%
- ROIV N/A
- EPS Growth
- WFG N/A
- ROIV N/A
- EPS
- WFG N/A
- ROIV N/A
- Revenue
- WFG $6,006,000,000.00
- ROIV $122,585,000.00
- Revenue This Year
- WFG $1.36
- ROIV N/A
- Revenue Next Year
- WFG $8.10
- ROIV N/A
- P/E Ratio
- WFG N/A
- ROIV N/A
- Revenue Growth
- WFG N/A
- ROIV 140.04
- 52 Week Low
- WFG $69.48
- ROIV $8.73
- 52 Week High
- WFG $102.40
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- WFG 51.47
- ROIV 50.06
- Support Level
- WFG $73.22
- ROIV $10.58
- Resistance Level
- WFG $77.38
- ROIV $11.77
- Average True Range (ATR)
- WFG 1.57
- ROIV 0.34
- MACD
- WFG 0.20
- ROIV -0.07
- Stochastic Oscillator
- WFG 60.89
- ROIV 17.65
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board, or OSB, producers in the world.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.